Abstract
The identification of drug metabolites in biofluids such as urine, plasma, and bile, as well as in in vitro systems, is an important step in drug discovery and development. Mass spectrometry, particularly when combined with high-performance liquid chromatography (HPLC-MS), can enable detailed structural information to be obtained on the metabolites of a drug or xenobiotic as a result of metabolism. The successful identification of drug metabolites by HPLC-MS-based techniques requires careful optimisation of a number of factors. First, the chromatographic separation should provide good resolution of the individual xenobiotic metabolites present in the sample. There is also the need to minimise the interference caused by the presence of endogenous metabolites, which may interfere with MS detection. Ideally, untreated samples should be profiled to reduce the likelihood of missing important metabolites due to losses during sample processing, but, depending upon the matrix, some degree of sample cleanup/extraction and concentration of the metabolites may be required using liquid–liquid or liquid–solid extraction. Second, the MS conditions must be carefully selected in order to maximise the potential of detecting the separated metabolites, which may have a very different character to the parent compound. The use of radiolabelled drugs in metabolism experiments greatly aids in the detection (and quantification) of metabolites, directing the investigator towards peaks that need to be characterised by MS. The presence of characteristic isotope patterns from either the incorporation of stable isotopes (e.g. 13C, 15N) or naturally occurring isotope patterns from substituents on the molecule (e.g. 35/37Cl, 79/81Br) can also provide a useful handle on the drug and its metabolites for the purposes of detection and spectrometric interpretation. This chapter provides guidelines for, and examples of, HPLC-MS-based drug metabolite profiling.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Ma, S., Chowdhury, S. K. (2008) Application of liquid chromatography/mass spectrometry for metabolite identification, in (Zhang, D., Zhu, M., Humphreys, W. G., eds.), Drug Metabolism in Drug Design and Development, pp. 319–368. Wiley, New Jersey.
Johnson, K. A., Plumb, R. (2005) Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J Pharm Biomed Anal 39, 805–810.
Zhu, M., Zhao, W., Humphreys, W. G. (2008) Applications of liquid radiochromatography techniques in drug metabolism studies, in (Zhang, D., Zhu, M., Humphreys, W. G., eds), Drug Metabolism in Drug Design and Development, pp. 319–368. Wiley, New Jersey.
Athersuch, T. J., Sison, R. L., Kenyon, A. S. J., Clarkson-Jones, J. A., McCormick, A. D., Wilson, I. D. (2008) Evaluation of the use of UPLC-tof/MS with simultaneous [14C]-radioflow detection for drug metabolite profiling: application to propranolol metabolites in rat urine. J Pharm Biomed Anal 48, 151–157.
Dear, G. J., Patel, N., Kelly, P. J., Webber, L., Yung, M. J. (2006) Topcount coupled to ultra-performance liquid chromatography for the profiling of radiolabeled drug metabolites in complex biological samples. J Chromatogr B 884, 96–103.
Lindon, J. C., Nicholson, J. K., Wilson, I. D. (1996) Direct coupling of chromatographic separations to NMR spectroscopy. Prog Nucl Magn Res 29, 1–49.
Scarfe, G. B., Wright, B., Clayton, E., Taylor, S., Wilson, I. D., Lindon, J. C., Nicholson, J. K. (1999) Quantitative studies on the urinary metabolic fate of 2-chloro-4-trifluoromethylaniline in the rat using 19F-NMR spectroscopy and directly coupled HPLC-NMR-MS. Xenobiotica 29, 77–91.
Duckett, C. J., Lindon, J. C., Walker, H., Abou-Shakra, F., Wilson, I. D., Nicholson, J. K. (2006) Metabolism of 3-chloro-4-fluoroaniline in rat using [14C]-radiolabelling, 19F-NMR spectroscopy, HPLC-MS/MS, HPLC-ICPMS and HPLC-NMR. Xenobiotica 36, 59–77.
Anari, M. R., Sanchez, R. I., Bakhtiar, R., Franklin, R. B., Baillie, T. A. (2004) Integration of knowledge-based metabolic predicitions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinvar. Anal Chem 76, 823–832.
Levesen, K., Schiebel, H. M., Behnke, B., Dotzer, R., Dreher, W., Elend, M., Thiele, H. (2005) Structure elucidation of phase II metabolites by tandem mass spectrometry: an overview. J Chromatogr A 1067, 55–72.
Drylab® (2000) Chromatography Optimisation Software, version 3.0.09, Molnar-Institut für Angewandte Chromatographie, Berlin, Germany.
Scarfe, G. B., Nicholson, J. K., Lindon, J. C., Wilson, I. D., Taylor, S., Clayton, E., Wright, B. (2002) Identification of the urinary metabolites of 4-bromoaniline and 4-bromo-[carbonyl-13C]-acetanilide in the rat. Xenobiotica 32, 325–337.
Shillingford, S., Bishop, L., Smith, C. J., Payne, R., Wilson, I. D., Edge, A. M. (2009) Application of high temperature LC to the separation of AZD5438 (4- (1-isopropyl-2-menythyl-1 H-imidazol-5-yl)-N-4(methylsulphonyl))phenyl]pyrimidin-2-amine) and its metabolites: comparison of UPLC and HTLC. Chromatographia 70, 37–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wilson, I.D. (2011). High-Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS)-Based Drug Metabolite Profiling. In: Metz, T. (eds) Metabolic Profiling. Methods in Molecular Biology, vol 708. Humana Press. https://doi.org/10.1007/978-1-61737-985-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-61737-985-7_10
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61737-984-0
Online ISBN: 978-1-61737-985-7
eBook Packages: Springer Protocols